IL320859A - Methods of treatment of breast cancer with selective estrogen receptor degraders (serds) - Google Patents
Methods of treatment of breast cancer with selective estrogen receptor degraders (serds)Info
- Publication number
- IL320859A IL320859A IL320859A IL32085925A IL320859A IL 320859 A IL320859 A IL 320859A IL 320859 A IL320859 A IL 320859A IL 32085925 A IL32085925 A IL 32085925A IL 320859 A IL320859 A IL 320859A
- Authority
- IL
- Israel
- Prior art keywords
- serds
- treatment
- methods
- breast cancer
- estrogen receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Nutrition Science (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263384170P | 2022-11-17 | 2022-11-17 | |
| PCT/EP2023/082015 WO2024105147A1 (en) | 2022-11-17 | 2023-11-16 | Methods of treatment of breast cancer with selective estrogen receptor degraders (serds) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL320859A true IL320859A (en) | 2025-07-01 |
Family
ID=88837606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL320859A IL320859A (en) | 2022-11-17 | 2025-05-12 | Methods of treatment of breast cancer with selective estrogen receptor degraders (serds) |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240180893A1 (en) |
| EP (1) | EP4618990A1 (en) |
| JP (1) | JP2025537840A (en) |
| KR (1) | KR20250108718A (en) |
| CN (2) | CN120202005A (en) |
| AU (1) | AU2023379941A1 (en) |
| IL (1) | IL320859A (en) |
| MX (1) | MX2025005711A (en) |
| TW (1) | TW202435871A (en) |
| WO (1) | WO2024105147A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025038481A1 (en) * | 2023-08-11 | 2025-02-20 | Arvinas Operations, Inc. | Vepdegestrant dosage regimen in cyp3a-inducer treatment in cancer |
| WO2025085738A1 (en) | 2023-10-18 | 2025-04-24 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and methods of treating disease |
| WO2025189056A1 (en) | 2024-03-08 | 2025-09-12 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and their use in treating disease |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI784255B (en) | 2014-12-18 | 2022-11-21 | 瑞士商赫孚孟拉羅股份公司 | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF |
| UA125824C2 (en) | 2016-10-24 | 2022-06-15 | Астразенека Аб | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer |
| IL266842B (en) | 2016-12-01 | 2022-09-01 | Arvinas Operations Inc | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders |
| TWI702219B (en) | 2018-07-12 | 2020-08-21 | 美商美國禮來大藥廠 | Selective estrogen receptor degraders |
-
2023
- 2023-10-23 US US18/492,216 patent/US20240180893A1/en active Pending
- 2023-11-16 WO PCT/EP2023/082015 patent/WO2024105147A1/en not_active Ceased
- 2023-11-16 EP EP23806287.1A patent/EP4618990A1/en active Pending
- 2023-11-16 CN CN202380079367.4A patent/CN120202005A/en active Pending
- 2023-11-16 KR KR1020257019840A patent/KR20250108718A/en active Pending
- 2023-11-16 JP JP2025528630A patent/JP2025537840A/en active Pending
- 2023-11-16 AU AU2023379941A patent/AU2023379941A1/en active Pending
- 2023-11-16 CN CN202511653595.5A patent/CN121129851A/en active Pending
- 2023-11-17 TW TW112144495A patent/TW202435871A/en unknown
-
2025
- 2025-05-12 IL IL320859A patent/IL320859A/en unknown
- 2025-05-15 MX MX2025005711A patent/MX2025005711A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20240180893A1 (en) | 2024-06-06 |
| JP2025537840A (en) | 2025-11-20 |
| KR20250108718A (en) | 2025-07-15 |
| MX2025005711A (en) | 2025-06-02 |
| AU2023379941A1 (en) | 2025-06-26 |
| EP4618990A1 (en) | 2025-09-24 |
| CN120202005A (en) | 2025-06-24 |
| TW202435871A (en) | 2024-09-16 |
| CN121129851A (en) | 2025-12-16 |
| WO2024105147A1 (en) | 2024-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL290789A (en) | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders | |
| SA521430055B1 (en) | Processes and compounds for the preparation of selective estrogen receptor degraders | |
| IL312680A (en) | Methods for treating cancer | |
| IL284850A (en) | Methods of treating breast cancer with tucatinib | |
| IL270716B (en) | Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer | |
| GB201901439D0 (en) | Method of predicting survival rates for cancer patients | |
| GB202018015D0 (en) | Composition and methods for the treatment of intestinal cancer | |
| AU2024225706A1 (en) | Methods for treating breast cancer | |
| MX2025005711A (en) | Methods of treatment of breast cancer with selective estrogen receptor degraders (serds) | |
| CA3273636A1 (en) | Methods of treatment of breast cancer with selective estrogen receptor degraders (serds) | |
| IL313886A (en) | Processes for the preparation of selective estrogen receptor degraders | |
| IL305780A (en) | Methods for the treatment of cancer | |
| PL4294395T3 (en) | Treatment of breast cancer using combination therapies comprising gdc-9545 and gdc-0077 | |
| GB202107994D0 (en) | Treatment of cancer | |
| EP4157246B8 (en) | Therapeutic combination for the treatment of breast cancer | |
| HK40099193A (en) | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders | |
| IL312155A (en) | Method of cancer treatment | |
| GB202016173D0 (en) | Demethylation apparatus and cancer therapy apparatus comprising same, and demethylation method and aparatus for cancer therapy using same | |
| HK40075586A (en) | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders | |
| IL314687A (en) | Treatment of cancer | |
| IL315444A (en) | Expression system for the treatment of cancer | |
| IL282471A (en) | Combination immunotherapy for treatment of triple-negative breast cancer | |
| IL279604A (en) | Apparatus for selective treatment of tissue | |
| PL3787632T3 (en) | Treatment regimen for the treatment of advanced oestrogen receptor positive breast cancer | |
| IL272390A (en) | Methods of treating cancer |